Clinical and Commercial License Agreement

RNS Number : 2611H

MaxCyte, Inc.

14 November 2018

 

MaxCyte, Inc.

("MaxCyte")

Precision BioSciences and MaxCyte Enter into

Clinical and Commercial License Agreement

Precision BioSciences gains rights to MaxCyte's cell engineering technology to develop next-generation, oncology-focused, cell therapies with Precision's ARCUS® genome-editing technology

DURHAM, NC, and GAITHERSBURG, MD, 14 November 2018 - Precision BioSciences (Precision) and MaxCyte (LSE: MXCT, MXCR) today announced they have entered into a non-exclusive, clinical and commercial license agreement that will allow Precision to use MaxCyte's Flow Electroporation® technologies to robustly deliver Precision's proprietary ARCUS genome-editing technology for use in next-generation gene edited allogeneic T-cell immunotherapies designed to treat a broad range of cancers.

David Thomson, Chief Development Officer of Precision, expressed his support for the agreement, noting, "Precision's therapeutic grade ARCUS editing platform is sufficiently compact and specific to use with a range of delivery systems. In considering these, we have found MaxCyte's electroporation technology complements our approach to allogeneic T cell manufacturing, which is focused on preserving cell quality throughout the process while maximizing overall yield." 

The clinical and commercial license builds upon an existing research and clinical license agreement between Precision and MaxCyte for the delivery of Precision's ARCUS technology into T-cells. MaxCyte will supply its technology platform to Precision as part of the license agreement and will receive future payments including milestones and technology access licensing fees.

"The initiation of this commercial license agreement with Precision, a leader in genome editing with its own proprietary ARCUS technology, signifies a key milestone for MaxCyte and demonstrates the value and versatility of our platform, our intellectual property, and our ability to foster important collaborations with companies generating life-changing gene therapies," said Doug Doerfler, President & CEO of MaxCyte, Inc.

MaxCyte's Flow Electroporation Technology enables the engineering of a variety of therapeutically-relevant cell types at high efficiency while maintaining high viability and recovery. Precision's lead allogeneic CAR T programs rely on genome editing, where ARCUS tools are used to transform healthy donor cells into therapeutics using the MaxCyte technology. These cell therapies can specifically target cancer cells in patients, potentially enabling a unique and specialized approach to cancer treatment. 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.

About Precision BioSciences

Precision BioSciences is dedicated to improving life. Our mission is to cure genetic disease, overcome cancer, and feed the planet. We are striving to achieve this goal with ARCUS, our therapeutic-grade, naturally-derived genome editing system that combines both specificity and efficacy to help overcome life's greatest genetic challenges. For additional information, please visit www.precisionbiosciences.com.

About MaxCyte

MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology platform to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® Technology platform to enable its biopharmaceutical industry partners to advance the development of innovative, cutting-edge medicines, particularly in cell therapy, including the use of gene editing tools in the treatment of inherited genetic diseases and immuno-oncology approaches to treating cancer.  The Company has placed its cutting-edge flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies, has more than 55 partnered programme licenses in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com

 For more information, visit www.maxcyte.com.

PRECISION CONTACT:

Media:

Precision BioSciences                                              [phone]

Heather King, Director, Marketing Communications and PR

MAXCYTE CONTACTS:

MaxCyte Inc.  Doug Doerfler, Chief Executive Officer  Ron Holtz, Chief Financial Officer		[phone]
Nominated Adviser and Broker  Panmure Gordon  Emma Earl  Freddy Crossley  Corporate Broking  James Stearns	[phone]
Financial PR Adviser  Consilium Strategic Communications  Mary-Jane Elliott  Chris Welsh  Sukaina Virji	[phone] [e-mail]

 

END

 

 

AGRXXLLFVFFBFBZ